GAPDH and neoplasm: Likewise, Johanna and colleagues confirmed that DLBCL is a highly metabolically active tumor, and that the metabolic status of DLCBL can predict the efficacy of mitochondrial metabolism disruptors in DLCBL with low GAPDH, which causes a poor prognosis of patients treated with R-CHOP.